‘We must speak the truth’: Liz Cheney defiant in speech ahead of ouster from top Republican job. The Wyoming representative stands by her opposition to Trump’s election lies as she prepares to be removed from No 3 House role
China Express Airlines, a regional carrier based in the southwestern city of Chongqing, is betting that its business model of flying heavily subsidised routes using an increasingly Chinese-made fleet will give it an edge over rivals. That put the previously obscure carrier on the radar of investors seeking faster-growing, domestic-focused alternatives to China's three biggest airlines. Shares in China Express, with a fleet of 52 mostly Western-made planes as well as 100 domestically manufactured jets on order, surged 56% last year and have risen close to 20% this year.
Nomura Holdings Inc raised its pretax income target for the next fiscal year by 14%, showing the long-cherished ambitions of Japan's top brokerage and investment bank to join the global elite remain undimmed, despite sustaining a near $3 billion hit from the collapse of U.S. investment fund Archegos. Setting out guidance in a mid-term presentation, Nomura on Wednesday said it was basing its raised target on a strategy of developing its footprint in global private markets, taking in business with unlisted companies, like private equity funds, as well as services for wealthier private clients. Nomura now estimates 320 billion yen ($2.94 billion) in pretax income for its three core divisions in the year from April next year, citing strength in wholesale arm, comprising global markets and investment banking.
Duryodhana could go to any extent to be on the Hastinapur throne.
Oslo, Norway –May 12, 2021 - IDEX Biometrics ASA, a leading provider of advanced fingerprint identification and authentication solutions, has appointed Catharina Eklof as Chief Commercial Officer (CCO), effective June 1, 2021. Catharina Eklof brings 20 years of global executive management across Financial Services, Retail, Travel, and Security. She has led commercialization of new customer-centric solutions across Fortune 500 companies. Catharina is currently CCO of Defentry AB, a cyber security company based in Stockholm, Sweden. She is also a member of the Board of Directors of Avanza Bank (Nasdaq: AZA), the largest securities brokerage in Sweden. Earlier in her career, Catharina spent more than 12 years with Mastercard International Inc. in Brussels, London, and New York, where she had a successful career, with successive leadership roles building innovative businesses leveraging Mastercard’s global transaction data. Catharina was instrumental in establishing Mastercard’s global strategic merchant program, bringing digital payment solutions and new, data-driven business models to organizations around the world. Catharina Eklof holds an MBA in International Business and a Master of Science in Economics from the University of Uppsala, Sweden. She will be based in Brussels, Belgium. Vince Graziani, Chief Executive Officer of IDEX Biometrics, commented: “I am very excited to welcome Catharina to our leadership team. Her considerable experience and expertise in security and card-based payment technologies will be extremely valuable to IDEX Biometrics as we continue to accelerate commercialization of our leading card-based authentication solutions.” For further information contact: Marianne Bøe, Investor Relations E-mail: firstname.lastname@example.org Tel: + 47 918 00186 Brett L Perry, U.S. Investor Relations E-mail: email@example.com Tel: + 1 214 272 0070 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies for smart cards, offering simple, secure, and personal touch-free authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices, or gain admittance to buildings with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity. For more information, visit www.idexbiometrics.com and follow on Twitter
Image source: The Motley Fool. Vital Farms, Inc. (NASDAQ: VITL)Q1 2021 Earnings CallMay 11, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and thank you for standing by.
Good day, and thank you for standing by and welcome to the Inari Medical Inc. Q1 2021 earnings conference call.[Operator Instructions] I would now like to hand the conference over to your speaker today, Caroline Corner of investor relations. Joining me on today's call are Bill Hoffman, president and chief executive officer; and Mitch Hill, chief financial officer.
NLOK earnings call for the period ending April 2, 2021.
Someone has hijacked my Amazon account but I can’t get into it. It seems rogue sellers have used it to generate fake reviews
Typo negative: the best and worst of Grauniad mistakes over 200 years. From ‘The Taming of the Screw’ to ‘irritable bowl syndrome’, the paper is fondly known for its slips
It’s none of my business how often you shower. But I can’t help wondering …. Rarely a week goes by without a new study announcing people have stopped washing. I know I should ignore them – but I’m gripped
HSBC has stakes in firms that plan more than 70 new coal plantsAsset management arm is not bound by pledge to stop financing coal even though new plants will emit hazardous air pollution The coal-fired Lethabo power station in South Africa. The country is planning more coal-fired facilities. Photograph: Siphiwe Sibeko/Reuters
DIY and homeware have been top of mind (and top of feed) for a minute now. Whether it's crocheting decorative objects or embracing the homespun styles of eras past (hi '70s), the objects we fill our homes with are more deliberately homemade and unique than ever.Nowhere is that more apparent than in the trend for tiled objects, especially cubes and side tables. It's perfect for displaying trinkets, plays with the trend for checkerboard and IG-friendly pastels, and can be made at home with spare tiles if you're feeling adventurous.If you're not though, there are plenty of independent makers whose tiled cubes can be made to order in a range of sizes and colours. Plus, the trend has expanded into other objects, from trinket boxes to frames to vases. Whether you want to go big or go small, there's a piece for every mood.Refinery29's selection is purely editorial and independently chosen – we only feature items we love! As part of our business model we do work with affiliates; if you directly purchase something from a link on this article, we may earn a small amount of commission. Transparency is important to us at Refinery29, if you have any questions please reach out to us.Studio Smiley currently makes a range of cubes and plinths to order over DM but is expanding soon to include benches and tables. Watch this space!Maza originally started making candles before branching out into tiled interiors. You can order a range of sizes and colours through the website.MAZA The Cube - Mini, $, available at MAZAWant your cube to do a bit more? They're perfectly suited to be planters, as shown in these Glass Jungle creations.GlassJungleGB Large Handmade Green Mosaic Tile Planter, $, available at EtsyIf you're looking for something on a much smaller scale, We Are Lazy Home makes tiled coasters to order through Instagram in block colours and checkerboard.The Dutch brand &Klevering always has its finger on the pulse when it comes to trends so it's no surprise to find it has its own range of tiled planters and vases.&klevering Pink Tile Vase, $, available at TrouvaAnother option is storage, like this adorable handmade trinkets box. Make and Relate Mosaic Tiled Trinket Box, $, available at EtsyAnd finally, another &Klevering joint – this time a tiled-style frame.&klevering Small Rectangle Check Photo Frame, $, available at Liberty LondonLike what you see? How about some more R29 goodness, right here?Uncomfortable Looking Cushions Are All The RageThis Spring, Say No To Boring MirrorsCrocheted Fruit & Fake Cakes Are Having A Moment
Nordecon AS and Kinnistud S OÜ, an Estmak Capital group company entered into contract for building the Class A energy rating apartment building with 48 apartments at Kuuseheki 54, Saue. The agreement includes performance of design and construction works of the building and utility networks. Extending over three above ground and one underground floors, this four-staircase building will have a gross area of 4,155 sqm and a net area of 3,500 sqm. The contract value is 3.6 million euros plus VAT. The building is due for completion in summer 2022. Nordecon (www.nordecon.com) is a group of construction companies whose core business is construction project management and general contracting in the buildings and infrastructures segment. Geographically the Group operates in Estonia, Sweden, Finland and Ukraine. The parent of the Group is Nordecon AS, a company registered and located in Tallinn, Estonia. The consolidated revenue of the Group in 2020 was 296 million euros. Currently Nordecon Group employs close to 710 people. Since 18 May 2006 the company's shares have been quoted in the main list of the NASDAQ Tallinn Stock Exchange. Andri HõbemägiNordecon ASHead of Investor RelationsTel: +372 6272 022E-mail: firstname.lastname@example.org
12 May 2021
Powerhouse Energy Group plc
NICE (Nasdaq: NICE) today announced the expansion of its operations in Japan, spearheading the launch of CXone. The industry’s leading Contact Center as a Service (CCaaS) platform, NICE CXone will be supported by a dedicated Japanese support and services team to assist customers with their transition to the cloud to address localization needs. Local cloud providers will be utilized to maintain in-country requirements and provide the highest standards in data security.
This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy dataThe Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021, subject to any COVID-19-related delays PARIS and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it has recruited the 155th participant for Part 2 of its COVA Phase 2-3 study of Sarconeos (BIO101) in patients infected with COVID-19. Recruitment of the 155th participant allows for the independent Data Monitoring Committee (DMC) to conduct its second interim analysis, based on safety and efficacy data, for the continuation of the trial in case of favorable results. The Company is to report the recommendations of the DMC based on its review of the second interim analysis results by the end of Q2 2021. The DMC previously delivered a favorable opinion in March on the safety of Sarconeos (BIO101) in COVID-19 and recommended the continuation of the study into Part 2, following the scheduled interim analysis of the 50 participants in Part 1 of the COVA study. Recruitment into Part 2 of the study continues to proceed in France and Brazil to complete enrollment of 310 participants, with the aim of filing for Emergency Use Authorization with the US Food and Drug Administration (FDA) and Conditional Approval with the European Medicines Agency (EMA) in Q3 2021. The final study results are expected in Q3 2021, subject to any COVID-19-related delays and the impact of the pandemic. Stanislas Veillet, President and CEO of BIOPHYTIS, said: “Completion of recruitment of the 155th patient is an important milestone for BIOPHYTIS as we will be able to measure the therapeutic potential of Sarconeos (BIO101) in COVID-19. We are now looking forward to the second interim analysis, and hope the DMC will recommend the continuation of our Phase 2-3 COVA trial upon favorable review of the safety and efficacy data.” The COVA clinical program (clinicaltrials.gov identifier NCT04472728) is a global, multicenter, double-blind, placebo-controlled, group-sequential and adaptive design two-part study. This Phase 2-3 study assesses Sarconeos (BIO101) in patients aged 45 and older, hospitalized with severe respiratory manifestations of COVID-19. The 155 participants were recruited in 34 centers in 4 countries: the US, Brazil, France and Belgium. Part 1 of the COVA Study is a Phase 2 exploratory proof of concept study providing preliminary data on the safety, tolerability, and activity of Sarconeos (BIO101) in 50 patients with severe respiratory manifestations related to COVID-19. Part 2 of the COVA Study is a Phase 3 randomized study investigating the safety and efficacy of Sarconeos (BIO101) on the respiratory function of 310 COVID-19 participants, or up to 465 participants, including the 50 participants from Part 1 of the study. The final sample size will depend upon DMC recommendations from the second interim analysis. About BIOPHYTISBIOPHYTIS SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com. DisclaimerThis press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding BIOPHYTIS’ anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that BIOPHYTIS considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in participant recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company’s clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to BIOPHYTIS or not currently considered material by BIOPHYTIS. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2020 Report available on BIOPHYTIS website (www.biophytis.com). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. BIOPHYTIS Contact for Investor RelationsEvelyne Nguyen, CFO email@example.com Media contactLifeSci Advisors Sophie Baumont/Chris MaggosE: firstname.lastname@example.org T: +33 6 27 74 74 49 Investor RelationsLifeSci Advisors, LLC Ligia Vela-ReidE: email@example.com
The Annual General Meeting in MSAB (publ) on 11 May 2021 decided to: Approve the income statement and the balance sheets in accordance with the presented Annual Report, and to discharge from liability the Board of Directors and the Chief Executive Officer.Approve the Board’s proposal of dividend of SEK 2.00 per share. The dividend payment date is set to 19 May 2021.Re-elect Jan-Olof Backman, Ann Hellenius, Linda Nyberg and Peter Gille as ordinary Board members. New elect Fredrik Nilsson and Bernt Ingman. Bernt Ingman is elected as the Chairman of the Board.Elect KPMG as the company’s external auditor with Mattias Lötborn as the Auditor-in-Charge for the period up to the conclusion of the next AGM.Approve the Nomination Committee’s proposal for Board remuneration in the amount of SEK 185,000 to Board members who are not also employed in the company, and SEK 500,000 to the Chairman of the Board. Approve the Board’s proposal for guidelines for remuneration of senior executives.Approve the Board’s remuneration report. Approve the Board’s proposal to authorize the Board of Directors to issue shares, share options or convertibles.Approve the Board’s proposal to authorize the Board of Directors to decide on transfer of own shares Approve the Board’s proposal to amend the Articles of Association.To appoint David Zaudy, Christian Hellman and Erik Ivarsson to the Nomination Committee. Board of Directors, May 2021 Contact: Bernt Ingman Chairman of the Board Tel: + 46 8 739 02 70 Contact:Daniel Hilmgård CFO Tel: +46 8 739 02 70 Email: firstname.lastname@example.org MSAB in briefMSAB is a world leader in forensic technology for extracting and analyzing data in seized mobile devices. The company develops high-quality and easy-to-use software for law enforcement organizations, such as police, military, and customs. The products, which have become a de facto standard for securing evidence in criminal investigations, can be supplemented with reporting tools and a large range of training with certifications within a holistic method for forensic science. The company serves customers in more than 100 countries worldwide, through its own sales offices and through distributors. MSAB is listed on Nasdaq Stockholm under the ticker name: MSAB B. www.msab.com Attachment Press Release MSAB resolutions from AGM 2021-05-11
12 May 2021 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM Cleantech Building Materials plc 5000 REFERENCE PROJECTS INSTALLED WITH ACCOYA® WOOD IN CHINA AND ASIA Cleantech Building Materials PLC (“CBM” or the “Company” or the “Group”) announces that last week it was revealed that Rome’s iconic Colosseum will be installing a new high-tech floor using Accoya® Wood to give visitors an idea of how the ancient Italian structure looked when gladiators fought there. Accoya® Wood was selected due to its light weight, sustainability credentials, and its ability to withstand outdoor elements for over 50 years. This week Accoya® Wood enjoyed another milestone, having achieved 5000 installations across China and Asia. These projects include famous sites such as Hong Kong Disneyland and the Shanghai Bund riverside promenade. One of the recent projects in China is the “Please be Seated” art pieces created by London’s Paul Cocksedge Studio and Swire Properties. Fabricated from 1,440 planks of sustainably sourced Accoya® Wood, this 15.2 metre-long installation features ‘waves’ of wood rising to form arches for people to walk through, and curves under to create space for people to sit, lie and relax. The "Please Be Seated" exhibition in China may be seen in the attached photo. On 31 March 2021, CBM announced the signing of a joint venture agreement with Nantong Acetic Acid Company to build the first Accoya® factory in Asia. The Group aims to have the first supply of China-produced Accoya® available for manufacturers of wood products and construction firms by early 2023. The Group’s joint venture factory will initially produce 40,000 m3 of Accoya® Wood, and the large land area where the factory is being built is capable of expanding up to 480,000 m3 of annual production. Accoya®-branded wooden products – such as windows, doors, decking and siding – are enjoying widespread acceptance in the European and US markets, as well as in China and Asia, and it is expected that the Group’s Asian manufacturer clients will be increasingly asked to fulfill that demand. THE DIRECTORS OF CLEANTECH BUILDING MATERIALS PLC ACCEPT RESPONSIBILITY FOR THE CONTENTS OF THIS ANNOUNCEMENT Further information may be found at the Company's website at www.cbm-plc.com Further Enquiries: Cleantech Building Materials plcAdrian Wyn-Griffithsinfo@cbm-plc.com+44 20 3934 6630Keswick Global AG (Certified Adviser)email@example.com +43 1 740 408045IFC Advisory Limited (Financial PR)Tim MetcalfeZach Cohen+44 20 3934 6630 Attachment Please Be Seated Exhibition